ARROWHEAD PHARMACEUTICALS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.00 per share for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-12-31 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-12-31 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-12-31 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-12-31 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $33.03.
- ARROWHEAD PHARMACEUTICALS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $0.00 10-Q · filed 2026-02-05 | |||
| 2025-09-30 | $0.00 10-K · filed 2025-11-25 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 | |||
| 2024-12-31 | $0.00 10-Q · filed 2025-02-10 | |||
| 2024-09-30 | $0.00 10-K · filed 2024-11-26 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $0.00 10-Q · filed 2024-02-06 | |||
| 2023-09-30 | $33.03 10-K · filed 2023-11-29 | |||
| 2023-06-30 | $33.03 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | $33.03 10-Q · filed 2023-05-02 | |||
| 2022-12-31 | $0.00 10-Q · filed 2023-02-06 | |||
| 2022-09-30 | $0.00 10-K · filed 2022-11-28 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | |||
| 2021-09-30 | $65.57 10-K · filed 2021-11-22 | |||
| 2021-06-30 | $65.57 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $65.41 10-Q · filed 2021-05-04 | |||
| 2020-12-31 | $63.64 10-Q · filed 2021-02-04 | |||
| 2020-09-30 | $48.19 10-K · filed 2020-11-23 | |||
| 2020-06-30 | $50.42 10-Q · filed 2020-08-05 | |||
| 2020-03-31 | $53.78 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $51.58 10-Q · filed 2020-02-05 | |||
| 2019-09-30 | $16.05 10-K · filed 2019-11-25 | |||
| 2019-06-30 | $14.18 10-Q · filed 2019-08-05 | |||
| 2019-03-31 | $13.26 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $13.73 10-Q · filed 2019-02-07 | |||
| 2018-09-30 | $5.97 10-K · filed 2018-12-11 | |||
| 2018-06-30 | $4.71 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $4.12 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $3.60 10-Q · filed 2018-02-09 | |||
| 2017-09-30 | $1.95 10-K · filed 2017-12-12 | |||
| 2017-06-30 | $1.95 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | $2.00 10-Q · filed 2017-05-03 | |||
| 2016-12-31 | $6.50 10-Q · filed 2017-02-06 | |||
| 2016-09-30 | $6.12 10-K · filed 2016-12-14 | |||
| 2016-06-30 | $6.12 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $6.12 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $5.96 10-Q · filed 2016-02-09 | |||
| 2015-09-30 | $6.35 10-K · filed 2015-12-14 | |||
| 2015-06-30 | $6.36 10-Q · filed 2015-08-04 | |||
| 2015-03-31 | $6.34 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $5.45 10-Q · filed 2015-02-09 | |||
| 2014-09-30 | $14.05 10-Q · filed 2015-08-04 | |||
| 2014-06-30 | $14.05 10-Q · filed 2014-08-12 | |||
| 2014-03-31 | $13.51 10-Q · filed 2014-05-06 | |||
| 2013-12-31 | $7.98 10-Q · filed 2014-02-04 | |||
| 2013-09-30 | $2.03 10-K · filed 2014-11-25 | |||
| 2013-06-30 | $2.03 10-Q · filed 2013-08-07 | |||
| 2013-03-31 | $2.20 10-Q · filed 2013-05-09 | |||
| 2012-12-31 | $2.54 10-Q · filed 2013-02-13 | |||
| 2012-09-30 | $4.40 10-Q · filed 2014-05-06 | |||
| 2012-06-30 | $4.96 10-Q · filed 2012-08-13 | |||
| 2011-09-30 | $5.86 10-K · filed 2012-12-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |